Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Advances in Therapy|July 31, 2012
Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritisYifei Liu, Eric Q Wu, Arielle G Bensimon, et al.Headache|November 1, 1989
Epidural blood patch in the treatment of post dural puncture headache: a double blind studyJ Seebacher, V Ribeiro, J L LeGuillou, et al.Clinical Drug Investigation|May 18, 2020
An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USAArielle G Bensimon, Zheng-Yi Zhou, Madeline Jenkins, et al.Journal of Medical Economics|April 24, 2019
Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United StatesArielle G Bensimon, Zheng-Yi Zhou, Madeline Jenkins, et al.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 15, 2010
Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertensionJoanne Chang, Weiyi Yang, Kristijan H Kahler, et al.Journal of Medical Economics|March 31, 2011
Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapyWeiyi Yang, Kristijan H Kahler, Thomas Fellers, et al.Journal of Medical Economics|February 23, 2026
Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United StatesFeng Qian, Arielle G Bensimon, Anjela Tzontcheva, et al.American Journal of Clinical Dermatology|November 30, 2010
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trialAlexa B Kimball, Arielle G Bensimon, Annie Guerin, et al.Current Medical Research and Opinion|July 23, 2020
Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinomaArielle G Bensimon, Yichen Zhong, Umang Swami, et al.Alimentary Pharmacology & Therapeutics|October 20, 2010
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapyS Lichtiger, D G Binion, D C Wolf, et al.Pageof 5